Volume 5.24 | Jun 24

Hematopoiesis News 5.24 June 24, 2014
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
 
TOP STORY
Researchers Discover that the Microenvironment that Controls Hematopoietic Stem Cells Can Be a Therapeutic Target for Myeloproliferative Disorders
Researchers have shown that the microenvironment that controls hematopoietic stem cells can be targeted for the treatment of a set of disorders called myeloproliferative neoplasias, the most prominent of which are chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, and atypical chronic myelogenous leukemia. [Press release from the Spanish National Cardiovascular Research Center discussing online prepublication in Nature] Press Release | Abstract
Take the "if" out of "diff": Reduce variability when differentiating to hematopoietic cells
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Chronic Variable Stress Activates Hematopoietic Stem Cells
The authors showed that stress increases proliferation of these most primitive hematopoietic progenitors, giving rise to higher levels of disease-promoting inflammatory leukocytes. They found that chronic stress induced monocytosis and neutrophilia in humans. While investigating the source of leukocytosis in mice, they discovered that stress activates upstream hematopoietic stem cells. [Nat Med] Abstract | Editorial

Altered Translation of GATA1 in Diamond-Blackfan Anemia
Investigators identified mutations in GATA1, encoding the critical hematopoietic transcription factor GATA-binding protein-1, that reduce levels of full-length GATA1 protein and cause Diamond-Blackfan anemia in rare instances. [Nat Med] Abstract

Purinergic P2Y14 Receptor Modulates Stress-Induced Hematopoietic Stem/Progenitor Cell Senescence
Scientists demonstrate that P2Y14 modifies cell senescence and cell death in response to tissue stress, thereby enabling preservation of hematopoietic stem/progenitor cell function. [J Clin Invest] Full Article

The Effects of Intestinal Tract Bacterial Diversity on Mortality following Allogeneic Hematopoietic Stem Cell Transplantation
Investigators examined the impact of intestinal diversity on subsequent mortality outcomes following transplantation. Fecal specimens were collected from 80 recipients of allogeneic hematopoietic stem cell transplantation at the time of stem cell engraftment. [Blood] Abstract | Press Release

Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myeloid Leukemia
Using an in silico gene expression-based screen for compounds evoking transcriptional effects similar to the anti-leukemia stem cell agent parthenolide, investigators identified AR-42, a novel histone deacetylase inhibitor that is structurally similar to phenylbutyrate, but with improved activity at sub-micromolar concentrations. [Mol Cancer Ther] Abstract

SL-401 and SL-501, Targeted Therapeutics Directed at the Interleukin-3 Receptor, Inhibit the Growth of Leukemic Cells and Stem Cells in Advanced Phase Chronic Myeloid Leukemia
After confirming that interleukin-3 receptor (IL3R) is highly expressed on CD34+/CD38 BCR-ABL1+ chronic myeloid leukemia stem cells, researchers investigated whether targeting IL3R with diphtheria toxin-IL3 fusion proteins SL-401 and SL-501 could eradicate these stem cells. [Br J Haematol] Abstract

A Stable and Reproducible Human Blood-Brain Barrier Model Derived from Hematopoietic Stem Cells
Scientists describe a method to generate a human blood brain barrier (BBB) model using cord blood-derived hematopoietic stem cells. The cells were initially differentiated into endothelial cells followed by the induction of BBB properties by co-culture with pericytes. [PLoS One] Full Article

TC1(C8orf4) Regulates Hematopoietic Stem/Progenitor Cells and Hematopoiesis
Researchers report that Tc1 regulates hematopoiesis in mice. Myeloid and lymphoid cells are increased markedly in peripheral blood of Tc1-deleted mice compared to wild type controls. [PLoS One] Full Article

CLINICAL RESEARCH

Sequential Myeloablative Autologous Stem Cell Transplantation and Reduced Intensity Allogeneic Hematopoietic Cell Transplantation Is Safe and Feasible in Children, Adolescents and Young Adults with Poor Risk Refractory or Recurrent Hodgkin and Non-Hodgkin Lymphoma
Investigators conducted a multi-center prospective study of myeloablative conditioning and autologous stem cell transplantation, followed by a reduced intensity conditioning and allogeneic hematopoietic cell transplantation in children, adolescents and young adults, with poor risk refractory or recurrent lymphoma. [Leukemia] Abstract

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in New-Onset Type 1 Diabetes: A Multicenter Analysis
Researchers determined the effects of autologous nonmyeloablative hematopoietic stem cell transplantation in 65 individuals with new-onset Type 1 diabetes who were enrolled in two Chinese centers and one Polish center, pooled, and followed up for 48 months. [Diabetes] Abstract

[Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.
 
REVIEWS
Next Generation Treatment of Acute Graft-versus-Host Disease
New insights into the roles played by novel cytokines, chemokines, intracellular signaling pathways, epigenetics and post translational modifications of proteins in graft-versus-host disease (GvHD) biology provide numerous targets that might be therapeutically exploited. This review highlights recent advances and identifies opportunities for reshaping contemporary GvHD therapeutics. [Leukemia] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

BioProcess International Conference & Exhibition - Boston MA
 
INDUSTRY NEWS
Dimension Therapeutics and Bayer HealthCare Enter Collaboration to Develop Novel Gene Therapy for Hemophilia A
Dimension Therapeutics announced it has entered into a collaboration with Bayer HealthCare for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. [Dimension Therapeutics] Press Release

MacroGenics Initiates Phase I Study of MGD006 for the Treatment of Acute Myeloid Leukemia
MacroGenics, Inc. announced that a first patient received drug in a Phase I study of MGD006 in relapsed or refractory acute myeloid leukemia. MGD006 is a humanized, Dual-Affinity Re-Targeting (DART®) bi-specific antibody-based molecule that binds to both CD123 and CD3, antigens expressed on leukemic cells and T lymphocytes, respectively. This study marks the first clinical trial of a DART product candidate. [MacroGenics, Inc.] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW EMBO Conference: Stem Cells in Cancer and Regenerative Medicine
October 9-12, 2014
Heidelberg, Germany

Visit our events page to see a complete list of events in the hematopoiesis research community.
 
JOB OPPORTUNITIES
NEW Scientific Manager – hES and iPS Cell Lines to Model Normal Hematopoiesis and Related Blood Diseases (St. Jude Children’s Research Hospital)

NEW Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

NEW Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Postdoctoral Research Fellow – Cardiovascular Immunology / Hematology (Massachusetts General Hospital)

Research Associate – Hematopoietic and Leukemic Stem Cells (Shanghai Jiao-Tong University School of Medicine)

Clinical HSCT Faculty Position – Pediatric Hematology-Oncology (University of Wisconsin School of Medicine)

Postdoctoral Fellow – Mammalian Hematopoietic and Erythroid Development (Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Regulation of Cytokine Receptor Signaling in Hematopoietic Stem Cells (University of Pennsylvania School of Medicine)

Postdoctoral Positions – New Models of Hematopoiesis and Hematopoietic Disorders (Icahn School of Medicine at Mount Sinai)

Postdoctoral Researcher – Cancer Genomics (University of Chicago)

Postdoctoral Associate – Hematopoietic Differentiation (Northwestern University Feinberg School of Medicine)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us